Strategic Global Investments, Inc.
Strategic Global Investments, Inc. STBV Peers
See (STBV) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Specialties Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| STBV | $0.00 | N/A | 472.00 | N/A | -$0.14 | N/A |
| BMXXY | $12.95 | N/A | 15.27B | 31.59 | $0.41 | +0.70% |
| EBOSY | $41.94 | N/A | 2.11B | 22.92 | $1.83 | +3.09% |
| XVIPY | $11.45 | -6.53% | 360.67M | N/A | N/A | N/A |
| EBRCZ | $0.55 | N/A | 203.39M | -4.57 | -$0.12 | N/A |
| TRXDW | $0.15 | -11.76% | 40.09M | N/A | N/A | N/A |
| NVNBW | $1.00 | N/A | 17.54M | -0.51 | -$1.95 | N/A |
| GWPC | $0.00 | N/A | 51950.00 | -0.01 | -$0.01 | N/A |
| SXHHF | $0.00 | +0.00% | 38133.00 | -0.01 | -$0.01 | N/A |
| KKUR | $0.00 | N/A | 8200.00 | N/A | N/A | N/A |
Stock Comparison
STBV vs BMXXY Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, BMXXY has a market cap of 15.27B. Regarding current trading prices, STBV is priced at $0.00, while BMXXY trades at $12.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas BMXXY's P/E ratio is 31.59. In terms of profitability, STBV's ROE is -1.13%, compared to BMXXY's ROE of +0.10%. Regarding short-term risk, STBV is more volatile compared to BMXXY. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.
STBV vs EBOSY Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, EBOSY has a market cap of 2.11B. Regarding current trading prices, STBV is priced at $0.00, while EBOSY trades at $41.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas EBOSY's P/E ratio is 22.92. In terms of profitability, STBV's ROE is -1.13%, compared to EBOSY's ROE of +0.08%. Regarding short-term risk, STBV is more volatile compared to EBOSY. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.
STBV vs XVIPY Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, XVIPY has a market cap of 360.67M. Regarding current trading prices, STBV is priced at $0.00, while XVIPY trades at $11.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas XVIPY's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to XVIPY's ROE of +0.10%. Regarding short-term risk, STBV is more volatile compared to XVIPY. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.
STBV vs EBRCZ Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, EBRCZ has a market cap of 203.39M. Regarding current trading prices, STBV is priced at $0.00, while EBRCZ trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas EBRCZ's P/E ratio is -4.57. In terms of profitability, STBV's ROE is -1.13%, compared to EBRCZ's ROE of -2.89%. Regarding short-term risk, STBV is more volatile compared to EBRCZ. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.
STBV vs TRXDW Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, TRXDW has a market cap of 40.09M. Regarding current trading prices, STBV is priced at $0.00, while TRXDW trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas TRXDW's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to TRXDW's ROE of -4.07%. Regarding short-term risk, STBV is more volatile compared to TRXDW. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.
STBV vs NVNBW Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, NVNBW has a market cap of 17.54M. Regarding current trading prices, STBV is priced at $0.00, while NVNBW trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas NVNBW's P/E ratio is -0.51. In terms of profitability, STBV's ROE is -1.13%, compared to NVNBW's ROE of -0.51%. Regarding short-term risk, STBV is more volatile compared to NVNBW. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.
STBV vs GWPC Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, GWPC has a market cap of 51950.00. Regarding current trading prices, STBV is priced at $0.00, while GWPC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas GWPC's P/E ratio is -0.01. In terms of profitability, STBV's ROE is -1.13%, compared to GWPC's ROE of N/A. Regarding short-term risk, STBV is more volatile compared to GWPC. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.
STBV vs SXHHF Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, SXHHF has a market cap of 38133.00. Regarding current trading prices, STBV is priced at $0.00, while SXHHF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas SXHHF's P/E ratio is -0.01. In terms of profitability, STBV's ROE is -1.13%, compared to SXHHF's ROE of +1.13%. Regarding short-term risk, STBV is less volatile compared to SXHHF. This indicates potentially lower risk in terms of short-term price fluctuations for STBV.
STBV vs KKUR Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, KKUR has a market cap of 8200.00. Regarding current trading prices, STBV is priced at $0.00, while KKUR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas KKUR's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to KKUR's ROE of N/A. Regarding short-term risk, STBV is more volatile compared to KKUR. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.
STBV vs OMRX Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, OMRX has a market cap of 5321.00. Regarding current trading prices, STBV is priced at $0.00, while OMRX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas OMRX's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to OMRX's ROE of -0.15%. Regarding short-term risk, STBV is less volatile compared to OMRX. This indicates potentially lower risk in terms of short-term price fluctuations for STBV.
STBV vs SCIE Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, SCIE has a market cap of 4924.00. Regarding current trading prices, STBV is priced at $0.00, while SCIE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas SCIE's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to SCIE's ROE of +0.00%. Regarding short-term risk, STBV is more volatile compared to SCIE. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.
STBV vs DGCRF Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, DGCRF has a market cap of 4304.00. Regarding current trading prices, STBV is priced at $0.00, while DGCRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas DGCRF's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to DGCRF's ROE of -1.11%. Regarding short-term risk, STBV is less volatile compared to DGCRF. This indicates potentially lower risk in terms of short-term price fluctuations for STBV.
STBV vs IBXG Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, IBXG has a market cap of 1975.00. Regarding current trading prices, STBV is priced at $0.00, while IBXG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas IBXG's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to IBXG's ROE of N/A. Regarding short-term risk, STBV and IBXG have similar daily volatility (163.64).
STBV vs DMSI Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, DMSI has a market cap of 1917.00. Regarding current trading prices, STBV is priced at $0.00, while DMSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas DMSI's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to DMSI's ROE of -0.32%. Regarding short-term risk, STBV is more volatile compared to DMSI. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.
STBV vs AAXT Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, AAXT has a market cap of 1599.00. Regarding current trading prices, STBV is priced at $0.00, while AAXT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas AAXT's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to AAXT's ROE of +0.54%. Regarding short-term risk, STBV is more volatile compared to AAXT. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.
STBV vs XCRP Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, XCRP has a market cap of 1516.00. Regarding current trading prices, STBV is priced at $0.00, while XCRP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas XCRP's P/E ratio is -0.00. In terms of profitability, STBV's ROE is -1.13%, compared to XCRP's ROE of -3.49%. Regarding short-term risk, STBV is less volatile compared to XCRP. This indicates potentially lower risk in terms of short-term price fluctuations for STBV.
STBV vs BMGP Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, BMGP has a market cap of 1265.00. Regarding current trading prices, STBV is priced at $0.00, while BMGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas BMGP's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to BMGP's ROE of -0.50%. Regarding short-term risk, STBV and BMGP have similar daily volatility (163.64).
STBV vs IMRSQ Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, IMRSQ has a market cap of 626.00. Regarding current trading prices, STBV is priced at $0.00, while IMRSQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas IMRSQ's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to IMRSQ's ROE of -1.30%. Regarding short-term risk, STBV and IMRSQ have similar daily volatility (163.64).
STBV vs OMDD Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, OMDD has a market cap of 310.00. Regarding current trading prices, STBV is priced at $0.00, while OMDD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas OMDD's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to OMDD's ROE of N/A. Regarding short-term risk, STBV is more volatile compared to OMDD. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.
STBV vs QMED Comparison
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 472.00. In comparison, QMED has a market cap of 17.00. Regarding current trading prices, STBV is priced at $0.00, while QMED trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas QMED's P/E ratio is -0.00. In terms of profitability, STBV's ROE is -1.13%, compared to QMED's ROE of N/A. Regarding short-term risk, STBV is more volatile compared to QMED. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.